Press releases

Hamlet BioPharma bjuder in till investerarmöte den 12 mars

March 12, 2025

Som tidigare meddelats bjuder Hamlet BioPharma in till månatligt investerarmöte
onsdagen den 12 mars, 2025, klockan 12.00.
Klicka på länken nedan för a7 delta på mötet.

https://us06web.zoom.us/j/87104238413?pwd=hdiuzRxbqxaBOcH8zz3dpKCxcyNzfc.1

För mer information, vänligen kontakta

Catharina Svanborg, VD, Hamlet BioPharma AB, +46 709 42 65 49,

catharina.svanborg@hamletpharma.com

Pressrelease – Lund, September 21st 2026 – Hamlet BioPharma’s monthly digital investors’ meeting on September 23rd

September 21, 2026

Pressrelease – Lund, September 17th 2026 – Successful patient enrolment in HAMLET BioPharma’s Phase III bladder cancer trial

September 17, 2026

Year-end Report (Q4) July 2025 – June 2026

August 28, 2026

Pressrelease – Lund, 27 Augusti, 2026 – Hamlet BioPharma bjuder in till pressträff den 28 augusti

August 27, 2026

Kommuniké från extra bolagsstämma i Hamlet BioPharma AB (publ) den 11 mars 2025

Strong Alpha1H treatment effects confirmed in patients with bladder cancer, in final analysis. Clinical study report is being completed for submission to the FDA.

An innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections.

Hamlet BioPharma AB
Klinikgatan 32
SE-222 42 Lund
info@hamletbiopharma.com
Org. no. 556568-8958

Subscribe to receive
Pressreleases and Newsletters

Hamlet BioPharma.